<DOC>
	<DOCNO>NCT01701453</DOCNO>
	<brief_summary>1 . Objective To test safety 6 month-duration DAPT compare conventional 12-month-or-longer duration second-generation DES implantation patient acute coronary syndrome . 2 . Hypothesis A 6-month duration DAPT non-inferior conventional 12-month-or-longer duration DAPT prevent occurrence major adverse cardiac cerebrovascular event ( MACCE ) 18-month second-generation DES implantation patient ACS</brief_summary>
	<brief_title>Safety 6-month Duration Dual Antiplatelet Therapy After Acute Coronary Syndromes ( SMART-DATE )</brief_title>
	<detailed_description>1 . Primary endpoint MACCE , define composite all-cause mortality , myocardial infarction , cerebrovascular event 18 month index procedure . 2 . Secondary endpoint Individual component primary endpoint 18-month index procedure Death , myocardial infarction ( MI ) 18-month index procedure Cardiac death 18-month index procedure Target vessel failure ( TVF ) : cardiac death , MI target vessel territory , target vessel revascularization ( TVR ) 18-month index procedure Major adverse cardiac cerebrovascular event ( death , MI , cerebrovascular event , revascularization [ MACCE ] ) 18-month index procedure Death , MI , cerebrovascular event , stent thrombosis BARC Type 2 , 3 , 4 , 5 18-month index procedure Death , MI , cerebrovascular event , stent thrombosis BARC Type 2 , 3 , 4 , 5 18-month index procedure</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Subject must ≥ 20 year . 2 . Subject able verbally confirm understandings risk , benefit treatment alternative receive percutaneous coronary intervention he/she his/her legally authorize representative provide write informed consent prior study related procedure . 3 . Subject must culprit lesion native coronary artery significant stenosis ( &gt; 50 % visual estimate ) eligible stent implantation . 4 . Subject must clinical diagnosis acute coronary syndrome include unstable angina myocardial infarction . The specific definition acute coronary syndrome , follow ; 1 ) STsegment elevation MI ( STEMI ) elevation STsegment 0.1 mV 2 contiguous ECG lead new left bundlebranch block elevate biomarkers myocardial necrosis 2 ) NonSTsegment elevation MI ( NSTEMI ) Elevated biomarkers myocardial necrosis ( troponin CKMB &gt; upper reference limit ) one follow 1 . Transient STsegment elevation depression , Twave change consistent myocardial ischemia 2 . Identification culprit lesion coronary angiography 3 ) Unstable angina An accelerate pattern recurrent episode chest pain rest minimal effort new STsegment depression least 0.05 mV , T wave inversion least 0.3 mV least 2 lead . The ECG criterion unstable angina base TACTICSTIMI 18 trial.28 5 . Target lesion ( ) must locate native coronary artery visually estimate diameter ≥ 2.25 mm ≤ 4.25 mm . 6 . Target lesion ( ) must amenable percutaneous coronary intervention 1 . The patient know hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Biolimus , Everolimus , Zotarolimus , Contrast medium ( Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . ) 2 . Patients active pathologic bleed 3 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 4 . Systemic ( intravenous ) Biolimus , everolimus , zotarolimus use within 12 month . 5 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 6 . History bleed diathesis , know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . An elective surgical procedure plan would necessitate interruption clopidogrel first 12 month post enrollment . 9 . Patients actively participate another drug device investigational study , complete primary endpoint followup period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>duration DAPT</keyword>
</DOC>